NCT02254421已完成2 期
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 17
- 主要终点
- Time-weighted Average Change in Nasal Respiratory Syncytial Viral (RSV) Load From Baseline to Day 9
研究概览
简要总结
The primary objective of this study is to evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV lower respiratory tract infection (LRTI).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Received an autologous or allogeneic HCT using any conditioning regimen
- •Evidence of new abnormalities on chest X-ray obtained < 48 hours prior to screening, determined to be consistent with LRTI by the local radiologist, relative to the most recent previous chest X-ray. If chest X-ray is not available, a chest X-ray must be obtained for screening.
- •Documented RSV in both the upper (eg, nasal swab, nasopharyngeal swab, nasal wash) and lower (eg, induced sputum, bronchoalveolar lavage, lung biopsy, but not spontaneous sputum) respiratory tract as determined by local testing (eg, polymerase chain reaction, direct fluorescence antibody, respiratory viral panel assay, or culture). All samples must have been collected ≤ 6 days prior to Day 1, or as determined at screening as per protocol.
- •An informed consent document signed and dated by the participant or a legal guardian of the participant and investigator or his/her designee.
- •A negative urine or serum pregnancy test is required for female participants (unless surgically sterile or greater than two years post-menopausal)
- •Male and female participants of childbearing potential must agree to contraceptive requirements as described in the study protocol
- •Willingness to complete necessary study procedures and have available a working telephone or email
排除标准
- •Related to concomitant or previous medication use:
- •Use of non-marketed (according to region) investigational agents within 30 days, OR use of any monoclonal anti-RSV antibodies within 4 months or 5 half-lives of screening, whichever is longer, OR use of any investigational RSV vaccines after HCT
- •Use of a moderate or strong cytochrome P450 enzyme inducer including but not limited to rifampin, St. John's Wort, carbamazepine, phenytoin, efavirenz, bosentan, etravirine, modafinil, and nafcillin, within 2 weeks prior to the first dose of study drug
- •Related to medical history:
- •Pregnant, breastfeeding, or lactating females
- •Unable to tolerate nasal sampling required for this study, as determined by the investigator
- •Known history of HIV/AIDS with a CD4 count <200 cells/μL within the last month
- •History of drug and/or alcohol abuse that, in the opinion of the investigator, may prevent adherence to study activities
- •Related to medical conditions:
- •Requiring invasive mechanical ventilation at the time of randomization
- •Documented to be positive for other respiratory viruses (limited to influenza, parainfluenza, human rhinovirus, adenovirus, human metapneumovirus, or coronavirus), from the lower respiratory tract sample as determined by local testing
- •Clinically significant bacteremia or fungemia within 7 days prior to screening that has not been adequately treated, as determined by the investigator
- •Clinically significant bacterial, fungal, or viral pneumonia within 2 weeks prior to screening that has not been adequately treated, as determined by the investigator
- •Excessive nausea/vomiting at screening, as determined by the investigator, or an inability to swallow pills that precludes oral administration of the investigational medical product (for individuals without an NG tube in place)
- •Any condition which, in the opinion of the investigator, would prevent full participation in this trial or would interfere with the evaluation of the trial endpoints
- •Related to laboratory results:
- •Creatinine clearance < 30 mL/min (calculated using the Cockcroft-Gault method)
- •Clinically significant aspartate aminotransferase/alanine aminotransferase, as determined by the investigator
- •Clinically significant total bilirubin, as determined by the investigator
- •Note: Other protocol defined Inclusion/Exclusion criteria may apply.
研究组 & 干预措施
Presatovir
Experimental
Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
干预措施: Presatovir (Drug)
Placebo
Placebo Comparator
Participants will receive placebo to match presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
干预措施: Placebo (Drug)
结局指标
主要结局
Time-weighted Average Change in Nasal Respiratory Syncytial Viral (RSV) Load From Baseline to Day 9
时间窗: Baseline to Day 9
The time-weighted average change, often referred to as the DAVG, provides the average viral burden change from baseline. The mean values presented were calculated using the ANCOVA model and are adjusted for baseline value and stratification factors.
次要结局
- Number of Supplemental O2-Free Days Through Day 28(Up to Day 28)
- Percentage of Participants Developing Respiratory Failure Requiring Mechanical Ventilation Through Day 28(Up to Day 28)
- Percentage of All-Cause Mortality Among Participants Through Day 28(Up to Day 28)
研究者
研究点 (17)
Loading locations...
相似试验
已完成
2 期
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory TractRespiratory Syncytial VirusNCT02254408Gilead Sciences189
已完成
2 期
Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) InfectionRespiratory Syncytial Virus InfectionNCT02135614Gilead Sciences189
已完成
2 期
Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) InfectionRespiratory Syncytial Virus (RSV)NCT02534350Gilead Sciences61
已完成
1 期
Respiratory Syncytial Virus Human Challenge in Healthy Adult VolunteersUpper Respiratory Tract InfectionNCT02484417National Institute of Allergy and Infectious Diseases (NIAID)32
招募中
2 期
RSV Vaccination in Immunocompromised Patients.RSV InfectionNCT06597916Medical University of Vienna200